Bimatoprost (Latisse)

Trade Name : LATISSE

Allergan, Inc.

SOLUTION/ DROPS

Strength 0.3 mg/mL

BIMATOPROST Prostaglandin Analog [EPC],Prostaglandins [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Bimatoprost (Latisse) which is also known as LATISSE and Manufactured by Allergan, Inc.. It is available in strength of 0.3 mg/mL per ml. Read more

Bimatoprost (Latisse) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • LATISSE
  • 1
  • Ensure the face is clean, makeup and contact lenses are removed. Once nightly, place one drop of n (bimatoprost ophthalmic solution) 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.n
  • Do not reuse applicators and do not use any other brush/applicator to apply n .n
  • Do not apply to the lower eyelash line .n
  • Additional applications of n will not increase the growth of eyelashes.n
  • Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.n
  • Apply nightly directly to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying applicators. Blot any excess solution beyond the eyelid margin. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator. ()n
  • Bimatoprost ophthalmic solution 0.3 mg/mL.n
  • Bimatoprost ophthalmic solution 0.3 mg/mL. ()n
  • Hypersensitivity. ()n
  • No data
  • Concurrent administration of n and intraocular pressure (IOP)-lowering prostaglandin analogs in ocular hypertensive patients may decrease the IOP-lowering effect. Patients using these products concomitantly should be closely monitored for changes to their IOP. ()n
  • Pigmentation of the eyelids and iris may occur. Iris pigmentation is likely to be permanent. (, )n
  • The following adverse reactions are described elsewhere in the labeling:n
  • Most common adverse reactions (incidence approximately 3% - 4%) are eye pruritus, conjunctival hyperemia, and skin hyperpigmentation. ()n
  • To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • No data
  • LATISSEn- Arrayn- Zn- Rn- Rn- Rn- Sn- En- Sn- N
  • Bimatoprost is a powder, which is very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water. n is a clear, isotonic, colorless, sterile ophthalmic solution with an osmolality of approximately 290 mOsmol/kg.n
  • Contains: Active:n- Preservative:n- Inactives:
  • No data
  • No data
  • LATISSEn- Arrayn- LATISSEn- Arrayn- primary endpoint
  • In this study, patients were also evaluated for the effect of n solution on the length, thickness and darkness of their eyelashes. Improvements from baseline in eyelash growth as measured by digital image analysis assessing eyelash length, fullness/thickness, and darkness were statistically significantly more pronounced in the bimatoprost group at weeks 8, 12, and 16.n
  • After the 16-week treatment period, a 4-week post-treatment period followed during which the effects of bimatoprost started to return toward baseline. The effect on eyelash growth is expected to abate following longer term discontinuation.n
  • LATISSEn- Array
  • 3 mL in a 5 mL bottle with 70 applicators NDC 0023-3616-70n
  • 5 mL in a 5 mL bottle with 140 applicators NDC 0023-3616-05n
  • Storage:
  • Advise the patient to read the FDA-approved patient labeling (Patient Information).n
  • FDA-approved Patient Labeling
  • PATIENT INFORMATION
  • LATISSEn- Arrayn- [la teece]
  • (bimatoprost ophthalmic solution) 0.03%n
  • Read the Patient Information that comes with n before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your physician about your treatment.n
  • What is hypotrichosis of the eyelashes?
  • Hypotrichosis is another name for having inadequate or not enough eyelashes.n
  • What is LATISSEn- Arrayn- solution?
  • LATISSEn- Array
  • Who should NOT take LATISSEn- Arrayn- ?
  • Do not use n solution if you are allergic to one of its ingredients.n
  • Are there any special warnings associated with LATISSEn- Arrayn- use?
  • LATISSEn- Arrayn- use on the skin of the upper eyelid margins at the base of the eyelashesn- DO NOT APPLYn- LUMIGANn- Arrayn- LATISSEn- Array
  • LATISSEn- Arrayn- LATISSEn- Array
  • It is possible for hair growth to occur in other areas of your skin that n frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using n .n
  • Who should I tell that I am using LATISSEn- Arrayn- ?
  • You should tell your physician you are using n especially if you have a history of eye pressure problems.n
  • You should also tell anyone conducting an eye pressure screening that you are using n .n
  • What should I do if I get LATISSEn- Arrayn- in my eye?
  • LATISSEn- Arrayn- LATISSEn- Array
  • What are the possible side effects of LATISSEn- Arrayn- ?
  • The most common side effects after using n solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. n solution may cause other less common side effects which typically occur on the skin close to where n is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.n
  • If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your physician's advice concerning the continued use of n solution.n
  • What happens if I stop using LATISSEn- Arrayn- ?
  • If you stop using n , your eyelashes are expected to return to their previous appearance over several weeks to months.n
  • Any eyelid skin darkening is expected to reverse after several weeks to months.n
  • Any darkening of the colored part of the eye known as the iris is NOT expected to reverse and is likely permanent.n
  • How do I use LATISSEn- Arrayn- ?
  • The recommended dosage is one application nightly to the skin of the upper eyelid margin at the base of the eyelashes only.n
  • Once nightly, start by ensuring your face is clean, makeup and contact lenses are removed. Remove an applicator from its tray. Then, holding the sterile applicator horizontally, place one drop of n on the area of the applicator closest to the tip but not on the tip (see ). Then immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes (where the eyelashes meet the skin) going from the inner part of your lash line to the outer part (see ). Blot any excess solution beyond the eyelid margin. Dispose of the applicator after one use.n
  • Repeat for the opposite upper eyelid margin using a new sterile applicator. This helps minimize any potential for contamination from one eyelid to another.n
  • Illustration 1n
  • Illustration 2n
  • DO NOT APPLYn- ONLYn- LATISSEn- Arrayn- LATISSEn- Arrayn- LATISSEn- Array
  • If any n solution gets into the eye proper, it is not expected to cause harm. The eye should not be rinsed.n
  • Don't allow the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination by common bacteria known to cause infections.n
  • Contact lenses should be removed prior to application of n and may be reinserted 15 minutes following its administration.n
  • Use of n more than once a day will not increase the growth of eyelashes more than use once a day.n
  • Store n solution at 36u00b0-77u00b0F (2u00b0-25u00b0C).n
  • General Information about LATISSEn- Array
  • Prescription treatments are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use n solution for a condition for which it was not prescribed. Do not give n to other people. It may not be appropriate for them to use.n
  • This leaflet summarizes the most important information about n solution. If you would like more information, talk with your physician. You can also call Allergan's product information department at 1-800-678-1605.n
  • What are the ingredients in LATISSEn- Arrayn- ?
  • Active ingredient:
  • Inactive ingredients:
  • u00a9 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners. Patented. See: www.allergan.com/patentsIrvine, CA 92612 Made in the U.S.A.n
  • 72303US17n
  • NDC 0023-3616-70n
  • Latissen
  • (bimatoprost ophthalmicsolution) 0.03%n n STERILE RALLERGANn n

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.